Last reviewed · How we verify
NCT05485883: TILUR
Tislelizumab Plus Lenvatinib in Stage III-IV RCC
Phase 2 trial testing Tislelizumab Lenvatinib in Advanced Kidney Cancer in 20 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Tianjin Medical University Second Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 July 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tislelizumab Lenvatinib — full drug profile →
Conditions studied
- Advanced Kidney Cancer — all drugs for Advanced Kidney Cancer →
Sponsor
Tianjin Medical University Second Hospital
Who can join
18 and older, any sex, with Advanced Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase II study to determine the efficacy and safety of Tislelizumab when given in combination with Lenvatinib as treatment for patients with the advanced kidney cancer . Patients will receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mechanisms of angiogenesis in tumour.
Zhang R, Yao Y, Gao H, Hu X. · · 2024 · cited 32× · PMID 38590656 · DOI 10.3389/fonc.2024.1359069 -
Renal cancer: signaling pathways and advances in targeted therapies.
Jiang A, Li J, He Z, Liu Y, et al · · 2024 · cited 18× · PMID 39092291 · DOI 10.1002/mco2.676 -
Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.
Su J, Zhang J, Wu Y, Ni C, et al · · 2024 · cited 3× · PMID 38694912 · DOI 10.3389/fphar.2024.1322473
Verify or expand the search:
- PubMed search for NCT05485883
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Tianjin Medical University Second Hospital trials
Trials by the same sponsor.
- NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
- NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
- NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05485883 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
- Last refreshed: 8 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05485883.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing